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Abstract
Background:  Multiple sclerosis (MS) is an immune-mediated disease of polygenic etiology.
Dissection of its genetic background is a complex problem, because of the combinatorial
possibilities of gene-gene interactions. As genotyping methods improve throughput, approaches
that can explore multigene interactions appropriately should lead to improved understanding of
MS.
Methods: 286 unrelated patients with definite MS and 362 unrelated healthy controls of Russian
descent were genotyped at polymorphic loci (including SNPs, repeat polymorphisms, and an
insertion/deletion) of the DRB1, TNF, LT, TGFβ1, CCR5 and CTLA4 genes and TNFa and TNFb
microsatellites. Each allele carriership in patients and controls was compared by Fisher's exact test,
and disease-associated combinations of alleles in the data set were sought using a Bayesian Markov
chain Monte Carlo-based method recently developed by our group.
Results: We identified two previously unknown MS-associated tri-allelic combinations:
-509TGFβ1*C,  DRB1*18(3), CTLA4*G and -238TNF*B1,-308TNF*A2,  CTLA4*G, which perfectly
separate MS cases from controls, at least in the present sample. The previously described
DRB1*15(2) allele, the microsatellite TNFa9 allele and the biallelic combination CCR5Δ32, DRB1*04
were also reidentified as MS-associated.
Conclusion:  These results represent an independent validation of MS association with
DRB1*15(2) and TNFa9 in Russians and are the first to find the interplay of three loci in conferring
susceptibility to MS. They demonstrate the efficacy of our approach for the identification of
complex-disease-associated combinations of alleles.
Published: 26 July 2006
BMC Medical Genetics 2006, 7:63 doi:10.1186/1471-2350-7-63
Received: 17 March 2006
Accepted: 26 July 2006
This article is available from: http://www.biomedcentral.com/1471-2350/7/63
© 2006 Favorova et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
Page 2 of 9
(page number not for citation purposes)
Background
Investigation of polygenic human diseases, which arise
from the combined contribution of multiple independ-
ently acting and/or interacting polymorphic genes,
remains a great challenge [1-3]. A common constituent of
the complexity that underlies the susceptibility to poly-
genic diseases is heterogeneity [3,4]. MS [MIM 126200] is
an immune-mediated hereditary disease [5,6], and can be
considered as a prototype for polygenic human diseases
[4]. The results of linkage-based whole genome screen
studies [7,8] and a global meta-analysis [9,10] document
the concept that MS is the result of the interaction of sev-
eral genes. The effects of individual genes are small or
modest, making association studies more informative
than others because of their greater statistical power
[1,11]. Association testing is extensively employed in can-
didate-gene studies, which are usually conducted in pop-
ulation-based case-control studies. To date, the HLA class
II  DRB1*1501/DQA1*0102/DQB1*0602 (DR2) haplo-
type is the only region repeatedly confirmed as being asso-
ciated with MS in most Caucasians [5,10]. Other
candidate genes for MS predisposition studies have been
selected mainly because their encoded proteins are
involved in autoimmune pathogenesis. These include
genes for immunorelevant molecules such as cytokines,
cytokine receptors, immunoglobulins, T-cell receptors
and specific adapter protein, potential autoantigens of the
myelin sheath, ICAM1, and others [12].
Some studies searched for candidate gene combinations
as MS risk factors; however, these studies have not yet
extended beyond MS associations with alleles of each can-
didate gene coupled with HLA DRB1 alleles [13-19]. To
examine the possibility that the combined effect of defi-
nite genes is a risk factor for a polygenic disease, it is nec-
essary to explore a massive number of potential
combinations of allelic variants identified at candidate-
gene polymorphic loci. This number grows exponentially
with the number of candidate variants that may interact,
causing computational and statistical restrictions on the
use of standard enumerational methodologies. In a recent
paper [20], we described a novel algorithm based on
Markov chain Monte Carlo exploration using a Bayesian
statistical basis, APSampler, which allows the exploration
of genotypes tied to phenotypic trait levels to identify pos-
sible combinations of allelic variants at multiple loci that
could affect disease development. The aim of this study is
to simultaneously examine multiple candidate genes in
single groups of unrelated MS patients and healthy unre-
lated controls, all of Russian descent, and to search for dis-
ease-associated combinations of allelic variants at
multiple loci using our novel nonparametric methodol-
ogy [20].
Methods
Subjects and DNA samples
Two hundred eighty six unrelated patients (110 men and
176 women, mean age 33 ± 12 years) had a diagnosis of
MS [21]. Of these 187 had a relapsing-remitting MS
course, 39 a primary progressive MS course, and 60 were
secondary progressive. The mean age at onset was 23 ± 9
years. Three hundred sixty-two unrelated controls (203
men and 159 women, mean age 30 ± 11 years) were stud-
ied. All controls were free of acute or chronic internal and
neurological diseases as determined by physical examina-
tions. All subjects were living in the Moscow area; both
their parents were ethnic Russians. Informed consent to
the study was obtained from all participants and was
approved by the local Ethical Committee. Blood was
adjusted to 25 mM EDTA. Genomic DNA was isolated
from 5 mL of peripheral blood by phenol-chloroform
extraction using standard procedures.
Genotyping
Investigated polymorphic loci (including SNPs, repeat
polymorphisms, and one insertion/deletion) and the
numbers of genotyped MS patients and controls for each
marker are presented in Table 1.
HLA DRB1 gene
For genomic typing of the DRB1 gene, a sequence-specific
primer (PCR-SSP) technique was used. The two-step PCR
allowed amplification of all known DRB1 alleles and their
separation into groups corresponding to the specificities
from DR1 to DR18 [22].
TNFa and TNFb microsatellites
For a length polymorphism analysis of (AC)n and (TC)n
microsatellites, designated as TNFa and TNFb, which are
located 3.5 kb upstream of the LT gene, nested PCR was
used. The second PCR was carried out in the presence of
[α-32P]dATP, then PCR products were treated by the Kle-
now fragment of DNA polymerase I and electrophoresed
in an 8% polyacrylamide sequencing gel [23].
SNPs in TNF gene
Genotyping of the -238A→G polymorphism was per-
formed by analysis of restriction fragment length poly-
morphism of PCR products (PCR-RFLP method). PCR
amplification was carried out using the exactly homolo-
gous forward primer, while the reverse primer contained
two sequence mismatches, which made it possible to eval-
uate mutation status using the restriction enzyme BamHI
[24]. Analysis of the -308G→A polymorphism was per-
formed by PCR-SSP [25]. For genotyping of the -376A→G
polymorphism, the PCR-SSP method was also used. The
forward primers are 5'-CTT TTT CCT GCA TCC TGT CTG
GAA A-3' for -376A and 5'-CTT TTT CCT GCA TCC TGT
CTG GAA G-3' for -376G, the common reverse primer wasBMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
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5'-TTC TGT CTC GGT TTC TTC TCC ATC G-3'. These
primers were constructed using free on-line software Gen-
eFisher-Interactive PCR Primer Design [26]. PCR was per-
formed in 10 μL volumes containing 0.1 units of Taq
polymerase (from SileksM, Moscow, Russia), 200 ng of
genomic DNA, 5 pmol of the reverse PCR primer, 5 pmol
of the sequence-specific PCR primer for allele A or 2.5
pmol of the sequence-specific PCR primer for allele G,
four dNTPs (each at 5 mM), 70 mM Tris HCl pH 9.0, 20
mM (NH4)2SO4, 0.025% Tween 20, 0.025% NP-40, 1.0
mM MgCl2. Thermocycling consisted of 35 cycles of 92°C
for 60 s, 60°C for 90 s, 72°C for 90 s. The resulting frag-
ment length was 238 bp.
SNPs in LT gene
Genotyping of the +252G→A and +319C→G polymor-
phisms was performed by PCR-RFLP method. For analysis
of the SNP +252G→A, PCR amplification was performed
and the product aliquots were digested using the restric-
tion enzyme NcoI[27]. In parallel, other aliquots of the
same PCR products were digested using the restriction
enzyme Alw21I (AspHI) for analysis of SNP +319C→G
[24].
SNPs in TGFβ1 gene
For genotyping of five SNPs in the TGFβ1 gene, four PCR
fragments were obtained (one PCR fragment was com-
mon for the SNP +869T→C (10Leu→Pro) and SNP
+915G→C (25Arg→Pro)). Then resulting fragments were
immobilized on Hybond-N+ membrane (Amersham
Pharmacia Biotech) followed by hybridization with
sequence-specific oligonucleotide probes (PCR-SSO
method). PCR conditions, primers and probes were as
those described in [28], hybridization procedure was
modified according to [29] as follows. Prehybridization
was performed for at least 2 h at 52°C in 3.0 M tetrameth-
ylammonium chloride (TMAC), 50 mM Tris HCl pH 8.0,
2 mM EDTA, 5×Denhardt's solution, 0.1% SDS, 100 ng/
mL heat-denatured herring sperm DNA and 10–20 pmol/
mL of unlabeled oligonucleotide probe specific for the
other allele. Then 10–20 pmol/mL of [γ-32P]ATP-labeled
allele-specific oligonucleotide was added and hybridiza-
tion was performed for at least 2 h at 52°C. The mem-
branes were washed at room temperature in 2×SSC for 30
min followed by 2 × 15 min in 2×SSC, 0.1% SDS. Then
the membranes were washed twice at 58°C in 3.0 M
TMAC, 50 mM Tris HCl pH 8.0, 2 mM EDTA, 0.1% SDS,
rinsed in 2×SSC and autoradiographed.
Table 1: Polymorphous loci at or near genes of immune response included in the database
Gene/marker Chromosome 
localization
Polymorphism type* [refSNP ID]** Names of alleles 
considered
Method of analysis 
(the restriction 
endonuclease used)
Numbers of 
genotyped MS 
patients/controls
DRB1 6p21 Allele groups corresponding to 
serological specificities DR1-
DR18(3)
01–18(3) [44] PCR-SSP 229/314
Microsatellite TNFa 6p21 (AC)n a1-a13[23] Nested PCR 121/103
Microsatellite TNFb 6p21 (TC)n b1-b7[23] Nested PCR 120/96
SNP -376A→G [rs1800750] A, G PCR-SSP 202/146
TNF 6p21 SNP -308G→A [rs1800629] A1, A2 PCR-SSP 223/222
SNP -238A→G [rs361525] B1, B2 PCR-RFLP (BamHI) 165/112
LT 6p21 SNP +252G→A N1, N2 PCR-RFLP (NcoI) 205/150
SNP +319C→G H1, H2 PCR-RFLP (AspHI) 202/147
SNP -509C→T [rs17551290] C, T PCR-SSO 119/295
SNP +72 wild type→C insertion wt, ins 198/340
TGFβ1 19q13 SNP +869T→C (10Leu→Pro) T, C 150/248
SNP +915G→C (25Arg→Pro) G, C 157/248
SNP +1632C→T (263Thr→Ile) C, T 178/109
CCR5 3p21 Wild type→32 base pair deletion wt, Δ 32 PCR 221/355
CTLA4 2q33 SNP +49A→G (17Thr→Ala) 
[rs231775]
A, G PCR-RFLP (BstEII) 168/209
Abbreviations used: CCR5 – CC chemokine receptor 5 gene; CTLA4 – cytotoxic T-lymphocyte-associated protein 4 gene; DRB1 – major 
histocompatibility complex class II DR β-chain gene 1; LT – lymphotoxin α gene; TGFβ1 – transforming growth factor β-1 gene; TNF – tumor 
necrosis factor gene; PCR – polymerase chain reaction; RFLP – restriction fragment length polymorphism; SSO – sequence-specific oligonucleotides; 
SSP – sequence-specific primers; ins – insertion; wt – wild type.
* All positions of the SNPs are indicated relative to transcriptional start sites except CTLA4 SNP +49, where +49 is the position from translational 
start site.
** RefSNP IDs (rs#) are given for SNPs submitted in PubMed NCBI dbSNP.BMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
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32 base pair deletion in CCR5 gene
CCR5 genomic typing was performed using one-step PCR
with primers flanking the region of the 32-nucleotide
deletion [30].
SNP in CTLA4 gene
Genotyping of SNP +49A→G in CTLA4  gene was per-
formed by PCR-RFLP analysis using the restriction
enzyme BstEII [31].
Database
The genotypes and personal data for all patients and con-
trols were entered into a database, together with clinical
characteristics for patients. Microsoft Visual FoxPro was
used to develop a standalone database management sys-
tem that was used for input and analysis of the data.
Search algorithm
We used the APSampler algorithm [20] that identifies
combinations (patterns) of alleles at different loci that are
potentially associated with a phenotypic trait. Here, we
provide a brief description of the algorithm. The a posteri-
ori probability for support of each pattern given the data
is evaluated using a likelihood obtained from a battery of
conditional rank sum statistics that insures that each pat-
tern is evaluated after removing the effect of other pat-
terns, as in a statistical adjustment for multiple regression.
Each step of the algorithm is an update of a current set of
allelic patterns by a variation of the Metropolis-Hastings
algorithm [32,33]. The sets of patterns that receive high
support from the data are stored as potential results. For
each pattern, only those individuals that have all the pat-
tern's alleles genotyped were considered. Thus the algo-
rithm proceeded from incomplete genotypic information,
temporarily omitting those individuals that cannot be
unambiguously classified into the pattern carriers and
non-carriers at a given step. The executable files for Win32
console and for FreeBSD, together with documentation,
are available free to academic users (contact AVF or MFO).
In the current application to the MS case-control data, the
prior probability that a locus has no effect on the pheno-
type was set to 0.99. This favored a priori the case in which
each locus has no effect on phenotype, so that the search
would not explore patterns with a very large number of
alleles, which are unlikely to be reliably investigated in
this data set. We looked for sets of 2 or 3 patterns.
Statistical analysis
To compare allelic distributions in MS patients and con-
trols and to verify the APSampler's results, we used
Fisher's exact test. The analysis was performed using the
GraphPad InStat software package and original computer
scripts under Microsoft Visual FoxPro. As a statistical con-
trol for systematic genotyping error and population strat-
ification, the expected genotype proportions according to
the Hardy-Weinberg equilibrium were calculated and
compared to observed genotypes. For polymorphic DRB1
and TNFa loci, the p-values were corrected for the number
of comparisons (13 in case of DRB1 allele groups and 12
in case of TNFa alleles) according to the Bonferroni
method. The p-values and corrected p-values (pcorr) were
considered to be significant at a level smaller than 0.01.
The odds ratio (OR) was calculated with a 95% confi-
dence interval (CI).
For the haplotype frequency estimation, for the linkage
disequilibrium test, and for the Hardy-Weinberg disequi-
librium test, the population genetics data-analyzing soft-
ware Arlequin (version 2.0) [34] was used. We considered
a linkage disequilibrium or a Hardy-Weinberg disequilib-
rium to be significant when the p-value from the Arlequin
output was less than or equal to 0.05. For estimation of
haplotype frequencies, the default parameters were used.
To assess the significance of the APSampler-discovered
patterns, we computed the Empirical Bayes false discovery
rate, which is the estimated fraction of patterns unrelated
to the phenotype among those that have a significance
score as high or higher than the pattern reported [35]. The
vector of disease labels was permuted in a balanced way
by assigning the same number of diseased and healthy
individuals to two groups generated by permutation. We
repeated the permutation 100 times and examined all
possible combinations with the same number of alleles as
the pattern considered. For each permutation and each
combination, we computed a test of association and
counted the fraction of these tests that were larger than the
observed test for the pattern.
Results
Individuals were genotyped at polymorphic loci at or near
genes of the immune response situated at chromosomes
2, 3, 6 and 19 (Table 1). The allelic carriership (pheno-
typic frequency) in case of biallelic candidate loci (Figure
1) did not differ significantly in MS patients and controls.
The allelic distributions of polymorphic candidate loci
showed a positive association of MS with a carriership of
allele group DRB1*15(2), corresponding to serological
specificity DR15(2) (pcorr<0.0001, OR = 3.1, CI is 2.1–4.6)
(Figure 2A), and with a carriership of a TNFa*9 microsat-
ellite allele (pcorr<0.01, OR = 7.9, CI is 1.8–35.0) (Figure
2B). The allelic distribution of the TNFb microsatellite,
which is adjacent to TNFa, did not differ significantly in
MS patients and controls (Figure 2C). It agreed with
TNFa/TNFb haplotype frequencies in patients and con-
trols, which were estimated from genotype data via the
population genetics data-analyzing software Arlequin ver-
sion 2.00 [34]. The predisposing TNFa9 allele was part of
three different haplotypes: TNFa9/TNFb1, TNFa9/TNFb4
and TNFa9/TNFb5 [see Additional File 1]. Both the HLABMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
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class II DRB1 gene and the class III TNFa microsatellite
map to 6p21 and were in linkage disequilibrium; how-
ever, the DRB1*15(2)/TNFa9 haplotype frequency esti-
mated from genotype data by the Arlequin software did
not exceed 1% [see Additional File 2]. This suggested that
DRB1 *15(2) and TNFa9 represented two independent
MS-predisposing markers. The fact that no alleles of the
tumor necrosis factor (TNF) and lymphotoxin α ( LT)
genes, also located at 6p21, differed significantly between
MS patients and controls (see Figure 1A) correlated with
the lack of strong linkage of TNF/LT  haplotypes with
DRB1*15(2) [see Additional File 3] and TNFa9 (not
shown).
Application of the APSampler algorithm [20] identified
five patterns that have a high probability of being associ-
ated with MS according to a multidimensional Wilcoxon-
based criterion. All the patterns identified deal with carri-
ership of alleles, without distinguishing homozygotes
from heterozygotes. Two of the patterns were the single
predisposing alleles DRB1*15(2) and TNFa9 discussed
above, while the third pattern was a predisposing biallelic
combination of CCR5Δ32 with DRB1*04, which was
recently described for this data set [15,20]. Importantly,
two new patterns comprising "trios" of allelic variants
were also identified. The first pattern included the C allele
of SNP -509 of the transforming growth factor β1 (TGFβ1)
gene, DRB1*18(3), and the G allele of the cytotoxic T-
lymphocyte antigen 4 (CTLA4) gene (trio 1). The second
pattern included the alleles -238TNF*B1, -308TNF*A2
and again, CTLA4*G (trio 2). Fisher's exact test gave p <
0.01 for the association of MS with both patterns, ORs
were equal to 18.0 (CI 1.0–330) for trio 1 and 17.4 (CI
1.1–300) for trio 2 (Table 2). To assess the probability
Phenotypic frequencies (%) of SNP alleles in Russian MS patients and healthy individuals Figure 1
Phenotypic frequencies (%) of SNP alleles in Russian MS patients and healthy individuals. The numbers of typed 
individuals are given in Table 1. A: TNF and LT gene polymorphic regions; B: TGF β1, CCR5 and CTLA4 gene polymorphic 
regions. For each SNP, phenotypic frequencies of both alleles are shown on the same axis of a radar chart; thick lines join all 
common and all rare alleles of SNPs presented, and SNP allele names are indicated on the vertices. The same data are pre-
sented in Additional Table 1 [see Additional File 4].BMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
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that the trio patterns found were truly associated with MS,
we also computed the false discovery rate, which was less
than 0.003. The algorithm was intended to identify pat-
terns as minimal allelic sets, in the sense that such a set
provides stronger evidence of association with MS than
any of its subsets. As shown above (Figures 1 and 2A),
none of the alleles involved in the trios were an individual
risk factor. For both trios, among individuals who have all
the three alleles genotyped, the difference in phenotypic
frequencies for two-element subsets between MS patients
and healthy subjects was insignificant, with p-values
always exceeding 0.025 (Table 2). So, both trios, which
gain Fisher's test p-values less than 0.01, were correctly
identified as minimal MS-associated allelic sets. The fact
that two alleles of the TNF gene were required to form trio
2 was in agreement with the data suggesting that TNF*B1
and TNF*A2 are not parts of a single widespread haplo-
type [see Additional File 3].
Discussion
Based on the results presented, several (partially overlap-
ping) subgroups may be identified in the common group
of Russian MS patients, depending on carriership of dis-
tinct minimal patterns of susceptibility including one
(DRB1*15(2) or TNFa9), two (CCR5Δ32, DRB1*04) and
three (-509TGFβ1*C,  DRB1*18(3),  CTLA4*G or -
238TNF*B1,-308TNF*A2, CTLA4*G) alleles of candidate
genes. These results are evidence of the genetic heteroge-
neity of MS.
MS associations with DRB1*15(2) and TNFa9 were previ-
ously identified in our studies of independent groups of
ethnic Russians [36,37] and were replicated here for a new
dataset of patients and control subjects. Thus, the HLA
class II DRB1*15(2) is validated in this study as being
associated with MS in Russians as in most other Cauca-
sians. As follows from our data, DRB1*15(2) and TNFa9
represent two independent predisposing markers, in
agreement with the proposal that two MS susceptibility
loci exist within the MHC [5,38].
In previous studies, identification of MS-predisposing
combinations of allelic variants at multiple loci consisted
in stratification of affected and unaffected individuals
mostly according to the carriership of MS-predisposing
DR2 haplotype or its constituents and a subsequent pair
comparison of phenotypic frequencies of distinct alleles
of another gene of interest in subgroups of MS patients
and controls. This kind of analysis found reliable associa-
tions of MS in subgroups of DRB1*15(2) (or
DQB1*0602)-positive or negative individuals with the
carriership of some alleles of genes coding TCRβ receptor
[14], TGFβ1 [16], CTLA4 [13], ICAM-1 [19] and inter-
leukin 4 receptor [18]. In our recent studies, we have
extended this approach and stratified individuals accord-
ing to any DRB1 phenotypes. For DRB1*04-positive indi-
viduals, associations of MS with CCR5Δ 32 mutation [15]
and with alleles of myelin basic protein (MBP) gene [17]
were found. The latter association was found also for
DRB1*05 positive individuals [17].
A novel nonparametric methodology used in this paper
provides the capability to explore potential combinations
of more than two allelic variants of polymorphic candi-
Phenotypic frequencies (%) of some polymorphous HLA loci  in the Russian population Figure 2
Phenotypic frequencies (%) of some polymorphous 
HLA loci in the Russian population. MS patients are 
shown by white bars and healthy individuals are shown by 
grey bars. The numbers of typed individuals are given in 
Table 1. A: HLA DRB1. B: TNFa microsatellite. C: TNFb 
microsatellite. For significant differences, pcorr values are 
shown near the corresponding bars, which are shaded.BMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
Page 7 of 9
(page number not for citation purposes)
date genes. Two previously unknown tri-allelic combina-
tions: -509TGFβ1*C,  DRB1*18(3),  CTLA4*G and -
238TNF*B1,-308TNF*A2, CTLA4*G, which perfectly sep-
arate cases from controls in the present sample, were iden-
tified. Importantly, at least within our data set, non-
overlapping subgroups of individuals bearing predispos-
ing trios 1 and 2 constitute about 5% and 9% of consid-
ered MS patients, respectively, and 0% of considered
healthy controls (see Table 2). This suggests that carrier-
ship of these patterns might predict MS development. Due
to the linkage disequilibrium of chromosomal loci, a
genetic epidemiological approach cannot prove unambig-
uously that a disease-associated gene is causal. However, a
biological role for the DRB1,  CCR5,  TGFβ1,  TNF  and
CTLA4 gene products in the pathogenesis of MS is plausi-
ble, and supports the idea that the genes are actual MS sus-
ceptibility genes.
Trios 1 and 2 have striking similarities that may determine
their MS-predisposing properties due to dysregulation of
inflammatory pathways by protein products encoded by
their genes. First, both trios include the allele G of the
gene for co-stimulatory molecule CTLA4, which is an
important inhibitor of T-cell activation [39]. Carriers of
the +49CTLA4*G allele in exon 1, coding for the peptide
leader sequence, are characterized by a reduced CTLA4
inhibitory function [40], i.e. by impaired negative regula-
tion of the immune response. Second, both trios include
alleles of cytokine genes which promote inflammatory
immune response owing to decreased level of antiinflam-
matory cytokine TGFβ1 (trio 1) or increased level of
proinflammatory cytokine TNF (trio 2). Indeed, it is
known that the circulating concentration of TGFβ1 is
under genetic control, being lower in carriers of the pro-
moter  -509TGFβ1*C allele, in comparison with -
509TGFβ1*T allele [41]. The -308TNF*A2 allele included
in trio 2 is more actively transcribed than -308TNF*A1
[42]. The sequence of the promoter region of -
238TNF*B1, another trio 2 TNF allele, suggests that it is
also associated with increased TNF expression [43]. In trio
1 (-509TGFβ1*C, DRB1*18(3), CTLA4*G) carriers, a two-
hit repression of negative regulation of the immune
response is coupled with a contribution of the HLA class
II DRB1*18(3), which is not associated alone with MS
(see Figure 2A). Characteristics of autoantigen presenta-
tion in MS by the products encoded by DRB1*18(3) have
not been studied; however, it is clear that presence of this
allele in trio 1 may be an important factor of the individ-
ual immune response regulation, supplementing effects
provided by two other alleles of the trio.
Our results support the notion that genetic susceptibility
to MS arises as a result of contribution of several predis-
posing alleles involved in the autoimmune inflammatory
response. The nature of the interplay between the alleles
in the trios remains unclear. If it arises as a result of a
cumulative effect of multiple hits, these patterns provide a
picture of small, individually insufficient changes com-
bining to provide an overall significant response leading
to predisposition to MS. However, this scenario does not
exclude possible epistatic interactions of genes involved in
the trios.
Conclusion
The results presented here provide the first identification
of a combination of more than two alleles conferring a
genetic predisposition to MS as a complex polygenic dis-
ease. The two newly identified trios perfectly separate
cases from controls, at least in the present sample, as
would occur in a classic monogenic dominant disease,
where all observed carriers are patients. Because of sample
size limitations, the result can only be considered as pre-
liminary. However, the biological properties of the genes
included in the identified trios suggest a coherent picture
of dysregulation of inflammatory pathways, implying the
validity of the MS-associated patterns and encouraging
Table 2: Phenotypic frequencies (carriership) of the three-allele combinations (trios) and their two-element subsets in Russian MS 
patients and healthy individuals
Allelic combinations MS patients, N (%) Controls, N (%) p-value# OR (95% CI)##
-509TGFβ1*C, DRB1*18(3), CTLA4*G (trio 1)* 5 (5.3) 0 (0) 0.0086 18.0 (1.0–330)
-509TGFβ1*C, DRB1*18(3) 5 (4.4) 2 (0.7) 0.029
-509TGFβ1*C, CTLA4*G 63 (61) 102 (58) 0.61
DRB1*18(3), CTLA4*G 5 (3.0) 2 (1.1) 0.26
-238TNF*B1,-308TNF*A2, CTLA4*G (trio 2)** 11 (8.7) 0 (0) 0.0033 17.4 (1.1–300)
-238TNF*B1,-308TNF*A2 13 (9.9) 6 (5.4) 0.26
-238TNF*B1, CTLA4*G 38 (30) 15 (17) 0.036
-308TNF*A2, CTLA4*G 26 (16) 15 (14) 0.73
* 99 MS patients and 154 controls were genotyped at these polymorphic loci of TGFβ1, DRB1 and CTLA4 genes.
** 126 MS patients and 87 controls were genotyped at these polymorphic loci of TNF and CTLA4 genes.
#p-values considered to be significant are given in bold face.
## OR (95% CI) values are shown for significant p-values.BMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
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efforts required to replicate associations in independent
data. The APSampler algorithm used to identify the pre-
disposing patterns is highly efficient, as it requires only
hours of computation time on a laptop computer for this
data set, and is flexible, as it can handle incomplete geno-
typic information. The algorithm provides a valuable
resource for the growing volume of polygenic disease-
related genomic data, allowing efficient exploration of
such data to identify genetic predisposition and potential
therapeutic targets.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
OOF and MFO set up the initial formulation of the prob-
lem. OOF organized the interaction between the medical,
genetic and algorithmic groups. OOF, AVF, GP and MFO
wrote the manuscript. AVF and MFO conceived of and
developed the algorithm and the software. ANB and EIG
diagnosed MS and recruited patients. ANB, MAS and TVA
recruited healthy controls. ANB, EIG and OOF selected
the candidate genes. TVA, MAS, ADA, and OGK per-
formed genotyping analysis. OGK, MAS and OOF inter-
preted the patterns identified by the algorithm. MAS, TVA
and AVF applied the software to the genotyping database
developed by TVA. GP provided expert statistical advice
used to significantly improve the algorithm.
Additional material
Acknowledgements
We thank Erica Golemis and Kenneth Morgan for very useful discussion 
and for advice. All authors from Russia thank Russian Foundation for Basic 
Research (05-04-48982-a and 04-04-49601-a). AVF thanks the Howard 
Hughes Medical Institute (55005610), the Ludwig Institute for Cancer 
Research (CRDF 12039), Russian Ministry of Science and Education (State 
Contract # 02.434.11008) and Russian Academy of Sciences Presidium Pro-
gram in Molecular and Cellular Biology. GP thanks NSF (DMS034211) and 
NCI (CA06973). MFO thanks NCI (support under CCSG grant CA06927), 
the National Library of Medicine (LM008932), and the Pennsylvania Depart-
ment of Health for support.
References
1. Hirschhorn JN, Daly MJ: Genome-wide association studies for
common diseases and complex traits.  Nat Rev Genet 2005,
6(2):95-108.
2. Thornton-Wells TA, Moore JH, Haines JL: Genetics, statistics and
human disease: analytical retooling for complexity.  Trends
Genet 2004, 20(12):640-647.
3. Threadgill DW, Hunter KW, Williams RW: Genetic dissection of
complex and quantitative traits: from fantasy to reality via a
community effort.  Mamm Genome 2002, 13(4):175-178.
4. Bomprezzi R, Kovanen PE, Martin R: New approaches to investi-
gating heterogeneity in complex traits.  J Med Genet 2003,
40(8):553-559.
5. Herrera BM, Ebers GC: Progress in deciphering the genetics of
multiple sclerosis.  Curr Opin Neurol 2003, 16(3):253-258.
6. Kalman B, Albert RH, Leist TP: Genetics of multiple sclerosis:
determinants of autoimmunity and neurodegeneration.
Autoimmunity 2002, 35(4):225-234.
7. Kenealy SJ, Babron MC, Bradford Y, Schnetz-Boutaud N, Haines JL,
Rimmler JB, Schmidt S, Pericak-Vance MA, Barcellos LF, Lincoln RR,
et al.: A second-generation genomic screen for multiple scle-
rosis.  Am J Hum Genet 2004, 75(6):1070-1078.
8. Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A, Daly
MJ, De Jager PL, Walsh E, Lander ES, et al.: A high-density screen
for linkage in multiple sclerosis.  Am J Hum Genet 2005,
77(3):454-467.
9. GAMES, Transatlantic Multiple Sclerosis Genetics Cooperative: A
meta-analysis of whole genome linkage screens in multiple
sclerosis.  J Neuroimmunol 2003, 143(1–2):39-46.
10. Kenealy SJ, Pericak-Vance MA, Haines JL: The genetic epidemiol-
ogy of multiple sclerosis.  J Neuroimmunol 2003, 143(1–2):7-12.
11. Risch NJ: Searching for genetic determinants in the new mil-
lennium.  Nature 2000, 405(6788):847-856.
Additional File 1
Additional Figure 1 – TNFa/TNFb haplotype frequencies in MS 
patients and controls . Haplotypes are designated in accordance with 
TNFa/TNFb allele names.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-7-63-S1.pdf]
Additional File 2
Additional Figure 2 – DRB1/TNFa haplotype frequencies in MS 
patients and controls . A: DRB1*01 -DRB1*03 alleles; B: DRB1*04 -
DRB1*09 alleles. Haplotypes are designated in accordance with DRB1/
TNFa allele names. Haplotypes with frequencies less than 0.5% both in 
MS patients and in controls are not shown.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-7-63-S2.pdf]
Additional File 3
Additional Figure 3 – TNF/LT haplotypes in MS patients and controls. 
A: TNF/LT haplotype frequencies in all MS patients and controls; haplo-
type designations and entering SNP alleles are shown below. B: Frequen-
cies of extended haplotypes including DRB1*15(2) and different TNF/LT 
haplotypes in all MS patients and controls. Haplotypes are marked in 
accordance with DRB1 allele name and TNF/LT haplotype designation 
given in A. For better visualization, the same axis scales were used.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-7-63-S3.pdf]
Additional File 4
Additional Table 1 – Phenotypic frequencies (%) of SNP alleles in Rus-
sian MS patients and healthy individuals
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-7-63-S4.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2006, 7:63 http://www.biomedcentral.com/1471-2350/7/63
Page 9 of 9
(page number not for citation purposes)
12. Dyment DA, Ebers GC, Sadovnick AD: Genetics of multiple scle-
rosis.  Lancet Neurol 2004, 3(2):104-110.
13. Alizadeh M, Babron MC, Birebent B, Matsuda F, Quelvennec E, Liblau
R, Cournu-Rebeix I, Momigliano-Richiardi P, Sequeiros J, Yaouanq J,
et al.: Genetic interaction of CTLA-4 with HLA-DR15 in mul-
tiple sclerosis patients.  Ann Neurol 2003, 54(1):119-122.
14. Dyment DA, Steckley JL, Morrison K, Willer CJ, Cader MZ, DeLuca
GC, Sadovnick AD, Risch N, Ebers GC: TCR beta polymorphisms
and multiple sclerosis.  Genes Immun 2004, 5(5):337-342.
15. Favorova OO, Andreewski TV, Boiko AN, Sudomoina MA, Ale-
kseenkov AD, Kulakova OG, Slanova AV, Gusev EI: The chemokine
receptor CCR5 deletion mutation is associated with MS in
HLA-DR4-positive Russians.  Neurology 2002, 59(10):1652-1655.
16. Green AJ, Barcellos LF, Rimmler JB, Garcia ME, Caillier S, Lincoln RR,
Bucher P, Pericak-Vance MA, Haines JL, Hauser SL, et al.: Sequence
variation in the transforming growth factor-beta1 (TGFB1)
gene and multiple sclerosis susceptibility.  J Neuroimmunol 2001,
116(1):116-124.
17. Guerini FR, Ferrante P, Losciale L, Caputo D, Lombardi ML, Pirozzi
G, Luongo V, Sudomoina MA, Andreewski TV, Alekseenkov AD, et
al.: Myelin basic protein gene is associated with MS in DR4-
and DR5-positive Italians and Russians.  Neurology 2003,
61(4):520-526.
18. Mirel DB, Barcellos LF, Wang J, Hauser SL, Oksenberg JR, Erlich HA:
Analysis of IL4R haplotypes in predisposition to multiple
sclerosis.  Genes Immun 2004, 5(2):138-141.
19. Nejentsev S, Laaksonen M, Tienari PJ, Fernandez O, Cordell H, Ruu-
tiainen J, Wikstrom J, Pastinen T, Kuokkanen S, Hillert J, et al.: Inter-
cellular adhesion molecule-1 K469E polymorphism: study of
association with multiple sclerosis.  Hum Immunol 2003,
64(3):345-349.
20. Favorov AV, Andreewski TV, Sudomoina MA, Favorova OO, Parmi-
giani G, Ochs MF: A Markov Chain Monte Carlo Technique for
Identification of Combinations of Allelic Variants Underlying
Complex Diseases.  Genetics 2005, 171(4):2113-2121.
21. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin
FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al.: Rec-
ommended diagnostic criteria for multiple sclerosis: guide-
lines from the International Panel on the diagnosis of
multiple sclerosis.  Ann Neurol 2001, 50(1):121-127.
22. Sudomoina MA, Boiko AN, Demina TL, Gusev EI, Boldyreva MN,
Trofimov D, Alekseev LP, Favorova OO: Connection of multiple
sclerosis in the Russian population with alleles of the major
histocompatibility complex DRB1 gene.  Mol Biol (Mosk) 1998,
32(2):291-296.
23. Nedospasov SA, Udalova IA, Kuprash DV, Turetskaya RL: DNA
sequence polymorphism at the human tumor necrosis factor
(TNF) locus. Numerous TNF/lymphotoxin alleles tagged by
two closely linked microsatellites in the upstream region of
the lymphotoxin (TNF-beta) gene.  J Immunol 1991,
147(3):1053-1059.
24. Gallagher G, Eskdale J, Oh HH, Richards SD, Campbell DA, Field M:
Polymorphisms in the TNF gene cluster and MHC serotypes
in the West of Scotland.  Immunogenetics 1997, 45(3):188-194.
25. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J: Tumor necrosis
factor alpha-308 alleles in multiple sclerosis and optic neuri-
tis.  J Neuroimmunol 1995, 63(2):143-147.
26. GeneFisher   [http://bibiserv.techfak.uni-bielefeld.de/genefisher]
27. Roth MP, Nogueira L, Coppin H, Clanet M, Clayton J, Cambon-Thom-
sen A: Tumor necrosis factor polymorphism in multiple scle-
rosis: no additional association independent of HLA.  J
Neuroimmunol 1994, 51(1):93-99.
28. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A,
Arveiler D, Luc G, Ruidavets JB, Poirier O: Polymorphisms of the
transforming growth factor-beta 1 gene in relation to myo-
cardial infarction and blood pressure. The Etude Cas-
Temoin de l'Infarctus du Myocarde (ECTIM) Study.  Hyperten-
sion 1996, 28(5):881-887.
29. Bignon JD, Fernandez-Vina MF: Technical Handbook: Twelfth
International Histocombatibility Workshop and Confer-
ence.  Paris: HLA et Me'decine; 1996. 
30. Sandford AJ, Pare PD: Direct PCR of small genomic DNA frag-
ments from serum.  Biotechniques 1997, 23(5):890-892.
31. Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Mar-
tinez Larrad MT, Teng WP, Park Y, Zhang ZX, Goldstein DR, et al.:
Insulin-dependent diabetes mellitus (IDDM) is associated
with CTLA4 polymorphisms in multiple ethnic groups.  Hum
Mol Genet 1997, 6(8):1275-1282.
32. Robert C, Casella G: Monte Carlo Statistical Methods.  New
York: Springer Verlag; 1999. 
33. Metropolis N, Rosenbluth A, Rosenbluth M, Teller A, Teller E: Equa-
tions of state calculations by fast computing machines.  J
Chem Phys 1953, 21:1087-1091.
34. Schneider S, Roessli D, Excoffier L: Arlequin: A software for pop-
ulation genetics data analysis. Ver 2.000.  2000 [http://
cmpg.unibe.ch/software/arlequin3/] .  G e n e t i c s  a n d  B i o m e t r y  L a b ,
Dept. of Anthropology, University of Geneva; Arlequin
35. Efron B, Tibshirani R, Storey JD, Tusher V: Empirical Bayes Anal-
ysis of a Microarray Experiment.  J Am Statist Assoc 2001,
96(456):1151-1160.
36. Boiko AN, Gusev EI, Sudomoina MA, Alekseenkov AD, Kulakova OG,
Bikova OV, Maslova OI, Guseva MR, Boiko SY, Guseva ME, et al.:
Association and linkage of juvenile MS with HLA-DR2(15) in
Russians.  Neurology 2002, 58(4):658-660.
37. Gusev E, Sudomoina M, Boiko A, Deomina T, Favorova O: TNF
gene polymorphisms: associations with multiple sclerosis
susceptibility and severity.  In Frontiers in multiple sclerosis Edited
by: O A, H O. London: Martin Dunitz; 1997:35-41. 
38. de Jong BA, Huizinga TW, Zanelli E, Giphart MJ, Bollen EL, Uitdehaag
BM, Polman CH, Westendorp RG: Evidence for additional
genetic risk indicators of relapse-onset MS within the HLA
region.  Neurology 2002, 59(4):549-555.
39. Alegre ML, Frauwirth KA, Thompson CB: T-cell regulation by
CD28 and CTLA-4.  Nat Rev Immunol 2001, 1(3):220-228.
40. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N,
Rieckmann P: A polymorphism in the human cytotoxic T-lym-
phocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell
activation.  Immunogenetics 2002, 54(1):1-8.
41. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe
JC, Carter ND, Spector TD: Genetic control of the circulating
concentration of transforming growth factor type beta1.
Hum Mol Genet 1999, 8(1):93-97.
42. Uboldi de Capei MU, Dametto E, Fasano ME, Rendine S, Curtoni ES:
Genotyping for cytokine polymorphisms: allele frequencies
in the Italian population.  Eur J Immunogenet 2003, 30(1):5-10.
43. Grove J, Daly AK, Bassendine MF, Day CP: Association of a tumor
necrosis factor promoter polymorphism with susceptibility
to alcoholic steatohepatitis.  Hepatology 1997, 26(1):143-146.
44. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA,
Geraghty DE, Hansen JA, Mach B, Mayr WR, et al.: Nomenclature
for factors of the HLA system, 2002.  Hum Immunol 2002,
63(12):1213-1268.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/7/63/prepub